ReviewTrends in cardiovascular medicine2009
Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.
Review in Trends in cardiovascular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function.The Journal of clinical endocrinology and metabolism · 2012Trial
- Polygenic modelling of treatment effect heterogeneity.Genetic epidemiology · 2020Article
- CETP, LIPC, and SCARB1 variants in individuals with extremely high high-density lipoprotein-cholesterol levels.Scientific reports · 2019Article
- Cholesterol efflux alterations in adolescent obesity: role of adipose-derived extracellular vesical microRNAs.Journal of translational medicine · 2019Article
- Identification of eight genetic variants as novel determinants of dyslipidemia in Japanese by exome-wide association studies.Oncotarget · 2017Article
- Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals.PloS one · 2012Article
- Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol.PLoS genetics · 2011Article
- PON-dering differences in HDL function in coronary artery disease.The Journal of clinical investigation · 2011Article
- Association of a polymorphism of BTN2A1 with dyslipidemia in East Asian populations.Experimental and therapeutic medicine · 2011Article
- The genetics of common kidney disease: a pathway toward clinical relevance.Nature reviews. Nephrology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Several high-profile failures of lipid-related therapeutics in clinical trials have led to intense interest in improved discovery and preclinical prioritization of potential targets. The careful study of patients with rare monogenic disorders has played a key role in establishing the causal role of cholesterol in atherosclerosis and highlighting viable drug targets. Systematic efforts to extend the association of common variants linked with lipid levels to coronary disease enable assessment of the vascular consequences of lifelong differences in lipids due to variation in specific molecules. This application of genetic epidemiology, termed Mendelian randomization, may prove useful in informing ongoing drug development efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.